Anthera’s Sollpura flops after phase 3
Anthera cut free it’s flopped late-arrange Lilly castoff Sollpura (liprotamase), and now looks for those feared "key choices". Sollpura was out-licensed by Lilly in 2014, and the written work had all the attributes of its failure, back in December 2016 when it posted the information from its stage 3 Solution test for cystic fibrosis patients which revealed enzyme deficiency that obstructs digestion.
Sanofi finally gave up on Alnylam’s rare genetic disease drug
Sanofi has walked out of Alnylam’s primary hyperoxaluria type 1 (PH1) drug Lumasiran, a rare genetic disease drug after assessing the phase 1/2 data Alnylam presented late...
